Pharmacotherapy for Methamphetamine/Amphetamine Use Disorder - A Systematic Review and Meta-analysis.

@article{Chan2019PharmacotherapyFM,
  title={Pharmacotherapy for Methamphetamine/Amphetamine Use Disorder - A Systematic Review and Meta-analysis.},
  author={Brian Chan and Michele Freeman and Karli K. Kondo and Chelsea K. Ayers and Jessica L Montgomery and Robin Paynter and Devan Kansagara},
  journal={Addiction},
  year={2019}
}
AIMS Addiction to methamphetamine/amphetamine (MA/A) is a major public health problem. Currently there are no pharmacotherapies for MA/A use disorder that have been approved for use by the US Food and Drug Administration or the European Medicines Agency. We reviewed the effectiveness of pharmacotherapy for MA/A use disorder to assess the quality, publication bias, and overall strength of the evidence. METHODS Systematic review and meta-analysis. We searched multiple data sources (MEDLINE… Expand
The impact of methamphetamine/amphetamine use on receipt and outcomes of medications for opioid use disorder: a systematic review
TLDR
Overall, existing research suggests people who use methamphetamine/amphetamines may have lower receipt of MouD, retention in MOUD, and opioid abstinence during MOUd. Expand
Non-pharmacological interventions for methamphetamine use disorder: a systematic review.
TLDR
While CM interventions showed the strongest evidence favouring the outcomes assessed, tailored CBT alone or with CM was also effective in the target population and should be considered as the first line of treatment for methamphetamine use disorder. Expand
A systematic review and meta-analysis of medications for stimulant use disorders in patients with co-occurring opioid use disorders.
TLDR
Co-occurring stimulant/opioid use disorder is an important problem for targeting future research, and medication trials for methamphetamine use disorder are lacking in this population. Expand
Psychosocial and pharmacologic interventions for methamphetamine addiction: protocol for a scoping review of the literature
TLDR
This research will enhance awareness of evidence addressing the effects of psychosocial and pharmacologic interventions for MUD/PMU overall and in sub-populations, both in terms of recent CPGs/reviews and primary studies; inspection of the latter will also help establish the feasibility of future syntheses to compare treatments. Expand
Treatment of stimulant use disorder: A systematic review of reviews
TLDR
There was sufficient evidence to support the efficacy of contingency management programs for treatment of stimulant use disorder, but psychostimulants, n-acetylcysteine, opioid agonist therapy, disulfiram and antidepressant pharmacological interventions were found to have insufficient evidence tosupport or discount their use. Expand
The 5‐HT2C receptor as a therapeutic target for alcohol and methamphetamine use disorders: A pilot study in treatment‐seeking individuals
TLDR
The data support the notion of 5‐HT2C receptors as a therapeutic target for drug and alcohol abuse and reduce self‐reported alcohol and amphetamine‐type substance use and craving in AUD and MUD participants, respectively. Expand
Neurobiology, Clinical Presentation, and Treatment of Methamphetamine Use Disorder: A Review.
TLDR
A need to better understand the complex neurobiology of methamphetamine use disorder and to develop interventions aimed at novel biological targets is needed and mental health professionals need to be trained in recognizing early cardiovascular and cerebrovascular warning signs to mitigate the mortality associated with methamphetamine use Disorder. Expand
Pharmacotherapy treatment of stimulant use disorder
  • Mei T. Liu
  • Medicine
  • The mental health clinician
  • 2021
Stimulant use disorder (SUD) is a public health problem in the United States that is associated with increased morbidity and mortality. Psychosocial interventions, such as cognitive behavioralExpand
Bupropion and Naltrexone in Methamphetamine Use Disorder.
TLDR
Among adults with methamphetamine use disorder, the response over a period of 12 weeks among participants who received extended-release injectable naltrexone plus oral extended- release bupropion was low but was higher than that among Participants who received placebo. Expand
Care-engaged individuals with polysubstance use in Northeastern US are undertreated for methamphetamine use disorder: a retrospective cohort study
TLDR
Individuals in this study had high prevalence of polysubstance use, particularly concomitant methamphetamine and opioid use, and would benefit from greater access to contingency management treatment, harm reduction resources, and resources to address adverse social determinants of health. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 37 REFERENCES
Efficacy and safety of psychostimulants for amphetamine and methamphetamine use disorders: a systematic review and meta-analysis
TLDR
Quantitative analyses showed no effect of psychostimulants for sustained abstinence or treatment retention, and the need for more rigorous studies in this research area was identified. Expand
Varenicline treatment for methamphetamine dependence: A randomized, double-blind phase II clinical trial.
TLDR
The results of this study indicate that 1 mg varenicline BID was not an effective treatment for MA dependence among treatment-seeking MA-dependent volunteers. Expand
Aripiprazole for the treatment of methamphetamine dependence: a randomized, double-blind, placebo-controlled trial.
TLDR
Compared with placebo, aripiprazole did not reduce methamphetamine use significantly among actively using, dependent adults. Expand
Pharmacological approaches to methamphetamine dependence: a focused review.
TLDR
Despite the lack of success in most studies to date, increasing efforts are being made to develop medications for the treatment of methamphetamine dependence and several promising agents are targets of further research. Expand
Mirtazapine to reduce methamphetamine use: a randomized controlled trial.
TLDR
The addition of mirtazapine to substance use counseling decreased methamphetamine use among active users and was associated with decreases in sexual risk despite low to moderate medication adherence. Expand
Atomoxetine for amphetamine-type stimulant dependence during buprenorphine treatment: A randomized controlled trial.
TLDR
The findings support clinical tolerability and safety and suggest potential efficacy of atomoxetine for treating ATS use disorder in this population of Participants with opioid and ATS dependence. Expand
A comparison of aripiprazole, methylphenidate, and placebo for amphetamine dependence.
TLDR
Methylphenidate is an effective treatment for reducing intravenous drug use in patients with severe amphetamine dependence and should be considered as a treatment for nausea, vomiting, and diarrhea. Expand
Topiramate for the treatment of methamphetamine addiction: a multi-center placebo-controlled trial.
TLDR
Topiramate does not appear to promote abstinence in methamphetamine users but can reduce the amount taken and reduce relapse rates in those who are already abstinent. Expand
Riluzole for treatment of men with methamphetamine dependence: A randomized, double-blind, placebo-controlled clinical trial
TLDR
Patients in the riluzole arm experienced significantly greater improvement on all the craving, withdrawal, and depression measures regarding mean score changes from baseline to endpoint and no significant difference was detected between the two arms in terms of incidence of adverse events. Expand
Randomized, placebo-controlled trial of sertraline and contingency management for the treatment of methamphetamine dependence.
TLDR
These data suggest sertraline is contraindicated for methamphetamine dependence, and provide support for the use of contingency management for treatment of methamphetamine dependence. Expand
...
1
2
3
4
...